NCATS' rare disease program backs stem cell project and Lilly R&D

09/12/2013 | NIH News

The NIH's National Center for Advancing Translational Sciences will fund four research projects related to blindness and heart conditions, and the funding marks the NCATS Therapeutics for Rare and Neglected Diseases program's first collaboration with a large drugmaker as well as its first use of stem cells. A University of California, Irvine, project will explore retinitis pigmentosa treatments using retinal progenitor cells. An Eli Lilly and Co. program will focus on the treatment of hypoparathyroidism with a long-acting parathyroid hormone analog.

View Full Article in:

NIH News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA